Validation of steps countering recorded with a smartwatch.

Background: Activity trackers are becoming increasingly popular in everyday life, sport and research. Accurate measurement of step counts is essential for understanding an individual's daily activity levels and promoting healthier lifestyles. As the sensor technology has become very sophisticated, such a device can be worn on the body for several hours or days without restricting the subject's daily activities.

Development of a plasma- and albumin-free recombinant von Willebrand factor.

Baxter has developed a recombinant therapy for treating von Willebrand's disease. Recombinant VWF is co-expressed with the rFVIII in CHO cells used to produce the rFVIII product Advate. This rVWF is used as a drug component for a rVWF-rFVIII complex drug product.

Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.

Background: Patients with hereditary emphysema are treated with alpha 1-antitrypsin (alpha 1-proteinase inhibitor [A1PI]) concentrates. High-resolution isoelectric focusing (IEF) analysis of A1PI shows that commercial A1PI products have different glycoisoform band patterns predominantly caused by varying degrees of C-terminal Lys truncation at position 394 from the A1PI molecule. Basic carboxypeptidases (CPs) are a group of enzymes that specifically cleave C-terminal basic amino acids (Arg or Lys) from peptides and proteins.

Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.

Background And Objectives: Because the current demand for alpha-1-protease inhibitor (A1PI) exceeds the available supply, we aimed to develop a process for purification of A1PI from plasma which would achieve the highest possible degree of purity, specific activity and yield.

Materials And Methods: A1PI was purified from Cohn fraction IV-1,4 using ethanol precipitation and Q-Sepharose chromatography. Ceramic hydroxyapatite chromatography was used as a final purification step.